J&J Study of HIV Vaccine in Subordinated-Saharan African Women Fails
31 Agosto 2021 - 01:39PM
Dow Jones News
By Colin Kellaher
Johnson & Johnson on Tuesday said it is ending a study of an
investigational HIV vaccine regimen after data showed the regimen
didn't provide sufficient protection against HIV infection in young
women in sub-Saharan Africa at high risk of acquiring HIV.
J&J was conducting the Phase 2b trial, known as the Imbokodo
study, along with partners including the Bill & Melinda Gates
Foundation and the National Institute for Allergy and Infectious
Diseases, as part of its push to develop an HIV vaccine.
J&J said the investigational vaccine was found to have a
favorable safety profile with no serious adverse events, and it
noted that its HIV vaccine program continues with a global Phase 3
study dubbed Mosaico that is testing the safety and efficacy of a
different composition of the HIV vaccine regimen among men who have
sex with men and transgender individuals.
The Imbokodo proof-of-concept efficacy study began in 2017,
reached full enrollment of about 2,600 young women in 2019 and
completed vaccinations in June 2020.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
August 31, 2021 07:24 ET (11:24 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
Grafico Azioni Johnson and Johnson (NYSE:JNJ)
Storico
Da Feb 2024 a Mar 2024
Grafico Azioni Johnson and Johnson (NYSE:JNJ)
Storico
Da Mar 2023 a Mar 2024